中国实用医药
中國實用醫藥
중국실용의약
CHINA PRACTICAL MEDICAL
2014年
8期
51-52
,共2页
子宫腺肌瘤%保守手术%可行性%复发率
子宮腺肌瘤%保守手術%可行性%複髮率
자궁선기류%보수수술%가행성%복발솔
Uterine adenomyoma%Conservative surgery%Feasibility%Recurrence rate
目的：探讨子宫腺肌瘤保守手术的可行性。方法回顾性分析本院行保守手术的12例子宫腺肌瘤患者的临床资料。结果12例均采用开腹手术,行保守性手术(局部病灶挖除术),手术顺利,术后予以药物配合左炔诺孕酮缓释系统(LNG-IUS)治疗,随访2~48个月,痛经全部缓解, CA125术前56.4~231.2 U/ml,平均值为(94.55±51.25)U/ml,术后6个月下降明显,平均值为(32.17±11.61)U/ml,和术前相比差异有统计学意义(t=4.656, P=0.001)。随诊超过6个月者10例(83.3%),复发率0%；不孕者2例,其中1例已孕32周。结论对于要求保留子宫的子宫腺肌瘤患者,在充分知情沟通下,行局部病灶挖除术,术后配合药物治疗是可行的,且近期复发率低。
目的：探討子宮腺肌瘤保守手術的可行性。方法迴顧性分析本院行保守手術的12例子宮腺肌瘤患者的臨床資料。結果12例均採用開腹手術,行保守性手術(跼部病竈挖除術),手術順利,術後予以藥物配閤左炔諾孕酮緩釋繫統(LNG-IUS)治療,隨訪2~48箇月,痛經全部緩解, CA125術前56.4~231.2 U/ml,平均值為(94.55±51.25)U/ml,術後6箇月下降明顯,平均值為(32.17±11.61)U/ml,和術前相比差異有統計學意義(t=4.656, P=0.001)。隨診超過6箇月者10例(83.3%),複髮率0%；不孕者2例,其中1例已孕32週。結論對于要求保留子宮的子宮腺肌瘤患者,在充分知情溝通下,行跼部病竈挖除術,術後配閤藥物治療是可行的,且近期複髮率低。
목적：탐토자궁선기류보수수술적가행성。방법회고성분석본원행보수수술적12례자궁선기류환자적림상자료。결과12례균채용개복수술,행보수성수술(국부병조알제술),수술순리,술후여이약물배합좌결낙잉동완석계통(LNG-IUS)치료,수방2~48개월,통경전부완해, CA125술전56.4~231.2 U/ml,평균치위(94.55±51.25)U/ml,술후6개월하강명현,평균치위(32.17±11.61)U/ml,화술전상비차이유통계학의의(t=4.656, P=0.001)。수진초과6개월자10례(83.3%),복발솔0%；불잉자2례,기중1례이잉32주。결론대우요구보류자궁적자궁선기류환자,재충분지정구통하,행국부병조알제술,술후배합약물치료시가행적,차근기복발솔저。
Objective To study the feasibility of uterine adenomyoma conservative Surgery. Methods Retros-pectively analyzed the clinical data of 12 cases of uterine adenomyoma of our hospital conservative surgery. Results 12 cases with open operation, with (local lesion invisible) conservative surgery, surgery goes well, postoperative left acetylene connaught progesterone slow-release system be drugs (LNG IUS) treatment, followed up for 2 to 48 months, all alleviate dysmenorrhea, CA125 preoperative 56.4~231.2 U/ml, average (94.55±51.25) U/ml, decreased significantly after 6 months, the average (32.17±11.61)U/ml, compared with the preoperative difference was statistically significant (t=4.656, P=4.656). Follow-up more than 6 months 10 cases (83.3%), recurrence rate 0%;infertility in 2 cases, one was at 32 weeks. Conclusion For reserve uterus myoma of uterus gland, under fully familiar with the communication, the invisible line local lesions, postoperative cooperate with drug treatment is feasible, and recent recurrencerate is low.
